Combination of Aspirin and an Anti-Clotting Drug Reduces Risk of Dialysis Access Failure – 2
Narrator: This is NIH Health Matters. A new study has demonstrated that by using a promising drug combination, an access, called an Artery-Vein graft, lasts longer. Dr. Catherine Meyers, at the National Institute of Diabetes and Digestive and Kidney says this is important.
Dr. Meyers: Because the failure rate is just so high.
Narrator: Artery-vein access grafts are used for hemodialisis, the most common form of kidney replacement therapy for people with kidney failure in the United States.
Dr. Meyers: By in large, patients that are treated chronically with hemodialysis need either an AV fistula or an AV graft.
Narrator: Grafts can fail because blood vessels narrow at the graft site, and clotting. For details, visit www.nih.gov. Health Matters is produced by the National Institutes of Health, part of the US Department of Health and Human Services.
About NIH Radio
NIH Radio offers free audio news programs from the National Institutes of Health, your reliable source for health information.
All NIH Radio content is in the public domain and can be used without charge or restriction provided that it is not used to misrepresent our agency nor used to suggest we endorse any private organization, product, or service.
NIH Radio is a service of the Office of Communications & Public Liaison.